Patent ID: 11869186
Assignee: ELUCID BIOIMAGING INC.
Field: Medical technology (Instruments)
Classification: CPC A  G | IPC A  G

Claim 16:
17. A method of identifying one or more contraindications associated with a combination of any two or more of a lipid-lowering therapy, an anti-inflammatory therapy, and an anti-diabetic therapy for a patient diagnosed with atherosclerotic cardiovascular disease, the method comprising:
receiving non-invasively obtained data related to a plaque from the patient;
accessing a systems biology model of atherosclerotic cardiovascular disease, wherein
(i) the systems biology model represents a plurality of pathways associated with atherosclerotic cardiovascular disease,
(ii) the plurality of pathways include one or more pathways corresponding, respectively, to all three of:
a) one or more of glycosylated low-density lipoprotein (glyLDL), oxidized low-density lipoprotein (αLDL), and minimally-modified low-density lipoprotein (mmLDL), or very-low-density lipoprotein (VLDL),
b) one or more of Interleukin-1 (IL-1), Interleukin-1 beta (IL1β), Tumor Necrosis Factor (TNF), Interleukin-12/23 (IL12/23), Interleukin-17 (IL17), or other cytokine molecule, and
c) one or more of Mammalian Target of Rapamycin (MTOR), Nuclear Factor kappa B-1 (NFκβ1), Intercellular Adhesion Molecule 1 (ICAM1), or Vascular Cell Adhesion Molecule 1 (VCAM1), and

(iii) the systems biology model includes a disease-associated molecule level for each molecule in the systems biology model;

updating the systems biology model using personalized levels of molecules derived from the non-invasively obtained data from the patient to generate a patient-specific systems biology model;
updating the patient-specific systems biology model with information relating to an effect on low-density lipoprotein (LDL) levels by a lipid lowering agent, inflammation levels by an anti-inflammatory agent, and glucose levels by an anti-diabetic agent based on known mechanisms of action of each of the agents;
simulating a therapeutic response by the patient to a combination of any two or more of the lipid lowering agent, the anti-inflammatory agent, and the anti-diabetic agent in the updated patient-specific systems biology model to obtain simulated therapeutic effects for two or more combinations;
comparing the updated patient-specific systems biology model with and without the simulated therapeutic effects for each of the two or more combinations; and
identifying one or more contraindications associated with the combination of any two or more of the lipid lowering agent, the anti-inflammatory agent, and the anti-diabetic agent based on the comparison; and
providing a report indicating one or more contraindications associated with the combination of any two or more of the lipid-lowering agent, the anti-inflammatory agent, and the anti-diabetic agent for the patient.